EZH2 and leukemia: We next generated primary MLL-AF9 or AML1-ETO9a leukemias in recipient mice using transformation of Ezh2−/− HSPCs and compared survival and phenotype to Ezh2+/+ leukemias generated by the same oncogenes (Fig. 3 a).